This Medical Devices Stock Has Several Catalysts, Says Bullish Analyst
This Medical Devices Stock Has Several Catalysts, Says Bullish Analyst
Teleflex Inc (NYSE:TFX) benefited in the first quarter from the surge in the interventional segment and other tailwinds.
泰利福公司（NYSE: TFX）在第一季度受益于介入式业务部门的激增和其他助推因素。
UroLift sales in the physician's office could bottom out at $49 million in 2024 and the franchise will be "less of a revenue headwind" from 2025, according to Piper Sandler.
根据派杰投资公司的说法，医生诊所的UroLift销售额可能在2024年达到4,900万美元，并且从2025年开始，该产品系列将成为“收入的帮助”，而非“拖累”产品系列。
The Teleflex Analyst: Matt O'Brien upgraded the rating for Teleflex from Neutral to Overweight, while raising the price target from $205 to $245.
泰利福分析师马特•奥布莱恩将泰利福的评级从中立提升至超重，同时将价格目标由205美元上调至245美元。
The Teleflex Thesis: UroLift sales, which has prevented the stock from performing in recent quarters, should trough in the second or third quarter this year, O'Brien said in the upgrade note.
奥布赖恩在升级公告中表示，UroLift的销售额曾使该公司股票在近几个季度的表现不佳，但这种局面应该在今年第二或第三季度触底。
Check out other analyst stock ratings.
查看其他分析师的股票评级。
The company's sole competitor in the IABP market, Getinge is "facing significant regulatory issues with its production and sale of product, which makes about $170M worth of annual revenue potentially available to Teleflex," the analyst wrote.
该公司在IABP市场上唯一的竞争对手，Geitnge公司正面临“生产和销售产品方面存在重大监管问题，这将使每年约1.7亿美元的收入潜在地可以转化为泰利福的收入，”，分析师写道。
He added that the impact of this could be felt in 2025, adding about 100-200 basis points to revenue and earnings growth.
他补充说，这可能会在2025年产生影响，为营业收入和创业板增长带来约100-200个基点的贡献。
"We continue to get good feedback on the Barrigel product that TFX acquired last year and believe this product could grow north of 20% for several years," O'Brien further stated.
奥布赖恩进一步指出：“我们继续收到关于TFX去年收购的Barrigel产品的好反馈，并认为该产品未来几年的增长可能超过20%。”
TFX Price Action: Shares of Teleflex had risen by 1.7% to $213.92 at the time of publication on Monday.
泰利福股票在周一出版时上涨了1.7%，报213.92美元。
Now Read:
现在就阅读吧:
- Trump Granted Partial Immunity By Supreme Court, Ruling Says 'The President Is Not Above The Law': Dissenting Justice Criticizes Mockery Of Constitution
- 最高法院授予特朗普部分豁免权，裁决称“总统不凌驾于法律之上”：反对意见的法官批评了违反宪法的行为。